US · Healthcare · Diagnostics & Research
EPS came in at 11.46 against a street estimate of 10.78 — a beat of 6.3%.
Analysts rate Mettler-Toledo International Inc a buy (4 buy, 9 hold, 0 sell out of 13) with an average price target of $1,452.50.
CONFIDENT MTD beat Q2 EPS by $0.70 on 4% organic growth. Raised full-year EPS guidance 10-11%. China surged 9%, emerging markets thriving. Margins expanded 100bps ex-FX. Management sees durable momentum in biopharma, automation, onshoring. Q2 2026 Asia/Rest of World +9% organic. China reacceleration driven by industrial automation, biopharma, battery investments. Emerging markets 18% of sales, growing faster than company average. Analysts probed durability of lab recovery, conservatism in H2 guidance, and timing of biopharma reshoring orders. Management emphasized innovation and market execution offsetting macro uncertainty; acknowledged tougher Q3 comps but signaled confidence in underlying momentum, with reshoring viewed as incremental and extending into 2027–2028. 2026-07-31…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.84% |
| Capital Research & Mgmt Co - Division 3 | 7.59% |
| Vanguard Capital Management, LLC | 6.60% |
| Vanguard Portfolio Management, LLC | 4.97% |
| State Street Corp | 4.70% |
| AllianceBernstein L.P. | 3.78% |
| T. Rowe Price Investment Management,Inc. | 3.65% |
| Bank of New York Mellon Corp | 3.51% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 METTLER-TOLEDO INTERNATIONAL INC. - FORM 8-K SUMMARY July 30, 2026 --- OTHER NOTABLE POINTS • Board Expansion and New Director Appointment: Mettler | 2026-08-03 |
| Quarterly report · Q2 2026 METTLER-TOLEDO INTERNATIONAL INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $1,027.3 million (Q2 2025: $983.2 million) – up 4.5% | 2026-07-31 |
| Results announced · Q3 2026 METTLER-TOLEDO INTERNATIONAL INC. – Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Reported Sales: $1,027.3 million, up 4% vs. prior year • Q2 2 | 2026-07-30 |
| Board / officer change · Q2 2026 METTLER-TOLEDO INTERNATIONAL INC. - FORM 8-K SUMMARY Filing Date: May 13, 2026 --- HEADLINE NUMBERS • CEO Long-Term Incentive (LTI) Grant (May 2026 | 2026-05-13 |
| Shareholder vote results · Q2 2026 METTLER-TOLEDO INTERNATIONAL INC. – STOCKHOLDER MEETING SUMMARY (May 7, 2026) HEADLINE NUMBERS • Total shares outstanding (record date March 9, 2026 | 2026-05-11 |
| Quarterly report · Q1 2026 METTLER-TOLEDO INTERNATIONAL INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Total net sales Q1 2026: $947.1 million (vs. $883.7 million Q1 2025) – increa | 2026-05-08 |
| Proxy statement · Q2 2026 METTLER-TOLEDO INTERNATIONAL INC. — 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine directors for one-year terms (m | 2026-03-18 |
| Annual report FY2025 METTLER-TOLEDO INTERNATIONAL INC. – FORM 10-K SUMMARY HEADLINE NUMBERS • Market value (as of June 30, 2025): $24.2 billion • Outstanding shares (as | 2026-02-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mettler-Toledo International Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.